Is there any clinically significant drug‑drug interaction between pantoprazole and lurasidone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Clinically Significant Drug-Drug Interaction Between Pantoprazole and Lurasidone

There is no clinically significant drug-drug interaction between pantoprazole and lurasidone, and these medications can be safely co-administered without dose adjustments.

Mechanism and Metabolic Pathways

The lack of interaction is explained by their distinct metabolic pathways:

  • Lurasidone is primarily metabolized by CYP3A4 1
  • Pantoprazole is mainly metabolized by CYP2C19 with minimal involvement of CYP3A4 2

The FDA label for lurasidone explicitly states that no dosage adjustment is required when administered with substrates of CYP3A4 (which pantoprazole is not a significant inhibitor of) 1. Similarly, pantoprazole's drug interaction profile shows it has minimal effect on CYP3A4-mediated metabolism 2, 3.

Evidence Supporting Safe Co-Administration

Pantoprazole has the lowest potential for drug interactions among PPIs. Multiple studies demonstrate that pantoprazole has weaker CYP enzyme inhibition compared to omeprazole and other PPIs 3, 4, 5. Research specifically shows pantoprazole does not significantly affect the pharmacokinetics of CYP3A4 substrates like midazolam, nifedipine, or carbamazepine 2.

For lurasidone, the FDA label identifies only strong and moderate CYP3A4 inhibitors/inducers as clinically relevant interactions 1. Pantoprazole does not fall into either category. The comprehensive drug interaction review for lurasidone 6 confirms that dose adjustments are only needed with:

  • Strong CYP3A4 inhibitors (ketoconazole, ritonavir) - contraindicated
  • Moderate CYP3A4 inhibitors (diltiazem, erythromycin) - reduce lurasidone dose by 50%
  • CYP3A4 inducers (rifampin, carbamazepine) - contraindicated or increase dose

Clinical Considerations

Lurasidone must be taken with at least 350 calories of food to optimize bioavailability 1, 7. This is the primary administration consideration, not drug interactions with pantoprazole.

While one study 8 showed pantoprazole decreased clozapine absorption by approximately 9% due to increased gastric pH, this mechanism would theoretically apply to lurasidone as well. However, this effect is not clinically significant and does not warrant dose adjustment, as the reduction is minimal and lurasidone has a wide therapeutic window.

Practical Recommendation

Prescribe both medications at their standard therapeutic doses without modification. For lurasidone, use 40-80 mg daily (up to 120 mg if needed) with food 1, 9. For pantoprazole, use standard doses of 40 mg daily (or 80 mg for refractory cases) 2, 10. No special monitoring beyond routine clinical assessment is required for this combination.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.